Boehringer Ingelheim
Boehringer, Teva, others hit with EU fines for drug-ingredient cartel
Five pharmaceutical companies, including the prominent global firm Boehringer Ingelheim, find themselves in the midst of a regulatory storm, facing ...
Anaptys reports positive results for its rare skin disease drug and seeks a partner for commercialization
AnaptysBio has unveiled promising phase 3 data for its rare skin disease drug candidate, indicating a potential challenge to Boehringer ...
Boehringer Ingelheim Adopts Dual-Pricing Strategy with Launch of Unbranded Humira Biosimilar
Boehringer Ingelheim, the company that recently introduced the first interchangeable biosimilar to AbbVie’s blockbuster drug Humira, is now embracing a ...
Zeiss and Boehringer Ingelheim Collaborate on AI Initiative to Detect and Address Eye Diseases Earlier
A groundbreaking collaboration between Zeiss Medical Technology and Boehringer Ingelheim is set to revolutionise the early detection and treatment of ...
Jardiance gets FDA green light for chronic kidney disease, challenging AstraZeneca’s rival drug
Shortly after securing European approval for the treatment of chronic kidney disease (CKD), Eli Lilly and Boehringer Ingelheim have achieved ...
Boehringer Ingelheim Enters Legal Fray Against Inflation Reduction Act, Citing Constitutional Concerns
The legal battle surrounding the Inflation Reduction Act (IRA) has intensified as pharmaceutical giant Boehringer Ingelheim joins the ranks of ...
Boehringer’s Obesity Drug with Dual Mechanism Ready for Phase III
Boehringer Ingelheim is forging ahead with its obesity drug candidate, survodutide, moving it into a Phase III program following promising ...
Boehringer Launches Pivotal Trial for Liposarcoma Drug
Boehringer Ingelheim has initiated a registration trial for its investigational therapy, brigimadlin, as a potential treatment for dedifferentiated liposarcoma (DDLPS), ...
Boehringer Ingelheim Soars with Jardiance Growth as US Kidney Disease Approval Looms
Source – Boehringer Ingelheim Boehringer Ingelheim is gearing up for the launch of Jardiance, a diabetes and heart failure drug, ...
Jardiance Receives EU Approval for Treating Chronic Kidney Disease (CKD), Posing a Strong Challenge to Forxiga
Source – Boehringer Ingelheim The European Union has granted approval for Boehringer Ingelheim and Eli Lilly’s SGLT2 inhibitor, Jardiance (empagliflozin), ...
Medicare prescription coverage for obesity is supported by legislation by Novo Nordisk, Eli Lilly, and Boehringer Ingelheim
Despite the considerable excitement surrounding the potential of new and potent obesity medicines, these drugs remain inaccessible to many Americans ...
The US FDA has approved the use of Jardiance (empagliflozin) to treat type II diabetes in children and adolescents aged 10 and older
Source – Eli Lilly On June 21, 2023, Boehringer Ingelheim and Eli Lilly and Company announced that the US Food ...
Boehringer Ingelheim’s Zantac arbitration is won by Sanofi
Source – Sanofi On 20 June 2023 in Paris, Sanofi reports that the International Chamber of Commerce tribunal has rejected ...
